Technical Analysis for GLMD - Galmed Pharmaceuticals Ltd.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 3.24 | -2.99% | -0.10 |
GLMD closed down 2.99 percent on Friday, November 1, 2024, on 2 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: Nov 20
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 1,2,3 Pullback Bullish | Bullish Swing Setup | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Down 5 Days in a Row | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Stochastic Reached Oversold | Weakness | -2.99% | |
| Wide Bands | Range Expansion | -2.99% |
| Alert | Time |
|---|---|
| Possible Inside Day | 1 day ago |
| Fell Below Lower Bollinger Band | 1 day ago |
| 60 Minute Opening Range Breakdown | 1 day ago |
| Down 5% | 1 day ago |
| Lower Bollinger Band Support | 1 day ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/20/2024
GalMed Medical Research Ltd. researches and develops proprietary drugs for the treatment of lipid metabolism related diseases. The company has developed a series of proprietary fatty acid bile-acid conjugates (FABACs) which selectively inhibit the enzyme Stearoyl-CoA Desaturase (SCD1), a key regulator in lipid metabolism. It's flagship clinical compound Aramchol (arachidyl amido cholanoic acid), has the potential to modify several of the key disorders related to lipid metabolism, including fatty liver, gallstones, diabetes, hyperlipidemia, cancer, and alzheimer's disease. The company is based in Tel Aviv, Israel. GalMed Medical Research Ltd. operates as a subsidiary of Galmed International Ltd.
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Acid Diabetes Alzheimer's Disease Lipid Medical Research Metabolism Hepatology Fatty Acids Fatty Liver Hyperlipidemia
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Acid Diabetes Alzheimer's Disease Lipid Medical Research Metabolism Hepatology Fatty Acids Fatty Liver Hyperlipidemia
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 23.8 |
| 52 Week Low | 2.73 |
| Average Volume | 3,344,139 |
| 200-Day Moving Average | 4.33 |
| 50-Day Moving Average | 4.77 |
| 20-Day Moving Average | 3.89 |
| 10-Day Moving Average | 3.96 |
| Average True Range | 0.77 |
| RSI (14) | 39.76 |
| ADX | 35.56 |
| +DI | 26.56 |
| -DI | 20.82 |
| Chandelier Exit (Long, 3 ATRs) | 2.88 |
| Chandelier Exit (Short, 3 ATRs) | 5.36 |
| Upper Bollinger Bands | 4.69 |
| Lower Bollinger Band | 3.09 |
| Percent B (%b) | 0.09 |
| BandWidth | 41.22 |
| MACD Line | -0.43 |
| MACD Signal Line | -0.37 |
| MACD Histogram | -0.0572 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.66 | ||||
| Resistance 3 (R3) | 3.66 | 3.52 | 3.59 | ||
| Resistance 2 (R2) | 3.52 | 3.41 | 3.52 | 3.57 | |
| Resistance 1 (R1) | 3.38 | 3.35 | 3.31 | 3.38 | 3.54 |
| Pivot Point | 3.24 | 3.24 | 3.21 | 3.24 | 3.24 |
| Support 1 (S1) | 3.10 | 3.13 | 3.03 | 3.10 | 2.94 |
| Support 2 (S2) | 2.96 | 3.07 | 2.96 | 2.91 | |
| Support 3 (S3) | 2.82 | 2.96 | 2.89 | ||
| Support 4 (S4) | 2.82 |
